In the phase II study (NCT02365597) that enrolled 99 patients with advanced urinary bladder cancers harboring FGFR3 point mutation or FGFR2/3-containing fusions receiving erdafitinib, the ORR was 40% with 3% of the patients getting a complete response, and the patients had a median PFS duration of 5.5 months and median overall survival (OS) duration of 13.8 months. This evidence concerns the gene FGFR3 and urinary bladder cancer.